Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

TIVICAY DIN 02461226

Status: Cancelled Post Market
Holder: VIIV HEALTHCARE ULC
Molecule: DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM)
Available to quote

Health Canada record

Active ingredient(s)DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 25 MG
Dosage formTablet
RouteOral
SchedulePRESCRIPTION
ClassHuman
ATCJ05AJ03 DOLUTEGRAVIR
Original market date20-Jun-2017
Current status date31-Dec-2024
SourceHealth Canada DPD

Establishment licence of the holder

ViiV Healthcare ULC — licence 101800, currently licensed, last inspection rating C (2025-09-17).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM)

DINProductCompanyFormStrengthStatus
02491753DOVATOVIIV HEALTHCARE ULCTabletDOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG; LAMIVUDINE 300 MGMarketed
02475774JULUCAVIIV HEALTHCARE ULCTabletDOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG; RILPIVIRINE (RILPIVIRINE HYDROCHLORIDE) 25 MGMarketed
02556782PMS-DOLUTEGRAVIRPHARMASCIENCE INCTabletDOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MGMarketed
02501457SANDOZ DOLUTEGRAVIRSANDOZ CANADA INCORPORATEDTabletDOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MGApproved
02511517TIVICAYVIIV HEALTHCARE ULCTablet For SuspensionDOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 5 MGMarketed
02414945TIVICAYVIIV HEALTHCARE ULCTabletDOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MGMarketed
02430932TRIUMEQVIIV HEALTHCARE ULCTabletDOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 50 MG; ABACAVIR (ABACAVIR SULFATE) 600 MG; LAMIVUDINE 300 MGMarketed
02461218TIVICAYVIIV HEALTHCARE ULCTabletDOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 10 MGCancelled Post Market

Notices of Compliance

NOCDateSubmissionReason
189672017-02-03Supplement to a New Drug Submission (SNDS)SEEKING EXPANSION OF PEDIATRIC INDICATION TO INCLUDE CHILDREN AGED 6 YEARS AND OLDER. TWO NEW TABLET STRENGTHS: 10 AND 25 MG TABLETS
Request a quote for TIVICAY

How to read a Canadian DIN record